Alphatec Holdings, Inc. (ATEC) · Oct 29, 2026 · Earnings
Miss — Non-GAAP EPS $0.09 vs ~$0.10 consensus; revenue $221.2M vs ~$225.2M
Alphatec earnings showed strong case growth and profitability, but weak biologics attachment drove a revenue miss and lower 2026 guidance.
Alphatec is building an integrated spine-surgery ecosystem around implants, imaging, navigation, monitoring and data, with growth increasingly dependent on converting rising procedure and surgeon activity into revenue. Its prior outlook called for roughly $882 million of 2026 revenue, $140 million of adjusted EBITDA and at least $20 million of free cash flow.
The quarter missed the market's bar. Revenue was $221.2 million, below the published consensus of roughly $225.2 million, while non-GAAP EPS was $0.09 versus approximately $0.10 expected. The company itself says third-quarter revenue fell short because of lower biologics attachment, confirming that the shortfall was not simply a model discrepancy. 〔0〕
| Q3 2026 | Q3 2025 | Consensus / prior guide | |
|---|---|---|---|
| Revenue (Financial Highlights) | $221.2M (-) | $196.5M | ~$225.2M |
| Non-GAAP EPS (Non-GAAP reconciliation) | $0.09 | $0.03 | ~$0.10 |
| Adjusted EBITDA (Third Quarter Highlights) | $38.3M (+46%) | $26.1M | |
| Adjusted EBITDA margin (Non-GAAP reconciliation) | 17.3% (+4.0 pts) | 13.3% | |
| FY26 revenue guide (Financial Outlook) | $862M | $882M | |
| FY26 adjusted EBITDA guide (Financial Outlook) | $137M | $140M | |
| FY26 free cash flow guide (Financial Outlook) | $10M | ≥$20M |
The underlying procedure engine is still working, but monetization broke down. Surgical revenue rose 14%, hardware revenue grew 17%, case volumes increased approximately 20%, and new surgeon adoption rose 25%. That is evidence of continued demand for the procedural platform, but the weaker biologics attachment means ATEC is capturing less revenue per case than its growth in activity would imply.
Profitability improved, but the guidance reset is the more important signal. Adjusted EBITDA reached $38 million, with margin expanding 400 basis points year over year, and the company generated $6 million of free cash flow. But management cut its full-year revenue outlook by about $20 million, adjusted EBITDA by about $3 million and free cash flow by roughly half, making the biologics issue a company-wide translation problem rather than a narrow quarterly miss.
The balance sheet leaves less room for execution errors. Cash fell to approximately $80 million from $161 million at year-end while inventories rose to approximately $207 million from $169 million, and stockholders' equity was negative $2 million at September 30, 2026 (Balance Sheets). The filing does not indicate an immediate funding event, but weaker cash generation raises the importance of fixing biologics attachment without adding further working-capital strain.
Bottom line: ATEC is still gaining surgeons and procedures and expanding margins, but the business is not translating that activity into revenue as expected. The lower full-year outlook makes this a genuine execution setback centered on biologics, not merely a routine quarterly miss.
Q4 earnings report and biologics execution update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!